Synergy Pharmaceuticals, Inc.

• SP-333 Targets Root Cause Of Irritable Bowel Syndrome

  By Jordo Bivona - February 22, 2013 | Tickers: AZN, LLY, IRWD, SLXP, SGYP

  Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort. While there is no drug to cure the condition yet, Irritable Bowel Syndrome can be managed with a number of drugs available. Synergy Pharmaceuticals (NASDAQ: SGYP) is among one of the few companies that are actively involved in looking for the right treatment for this disorder. In more »

• Big Growth Stories in Biotech

  By Streetwise Reports - February 19, 2013 | Tickers: IRWD, SGYP, TSRX

  By George S. Mack of The Life Sciences Report.

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

   

  Bacteria are pure survivalists, and over billions of years they have evolved to produce ever-newer chemicals to protect themselves against other bugs, and in the last 100 years they have begun to protect themselves against the antibiotics that humans have developed from those more »

• Will This Irritable Bowel Syndrome Drug Be a Cash Cow?

  By Jordo Bivona - January 25, 2013 | Tickers: BMY, IRWD, MRK, PFE, SGYP

  As embarrassing and difficult to manage as chronic constipation and irritable bowel syndrome (IBS) are, there are surprisingly very few treatments available for patients at the moment. The treatments that do exist often cause diarrhea and nausea as side effects. Synergy Pharmaceuticals (NASDAQ: SGYP) has been focusing on its lead investigational drug Plecanatide, which is aimed at treating chronic constipation and constipation predominant irritable bowel syndrome.

  Plecanatide is currently in more »